phase readout
saveNCT05228470: A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
COMPLETEDupdated 7d ago
community read0 votes
Sponsor: Pfizer. Phase: PHASE2. Conditions: Elranatamab, Myeloma, Multiple Myeloma, Relapsed Multiple Myeloma, Refractory Multiple Myeloma, PF-06863135, BCMA, Bispecific, Bispecific Antibody, BCMA-CD3 Bispecific, MagnetisMM-8
view source ↗
comments(0)
5-min edit window · permanent after that